- Home
- AIV vs AUPH Comparison
AIV vs AUPH Comparison
Compare AIV & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIV
- AUPH
- Stock Information
- Founded
- AIV 1975
- AUPH 1993
- Country
- AIV United States
- AUPH Canada
- Employees
- AIV N/A
- AUPH N/A
- Industry
- AIV Real Estate Investment Trusts
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- AIV Real Estate
- AUPH Health Care
- Exchange
- AIV Nasdaq
- AUPH Nasdaq
- Market Cap
- AIV 1.2B
- AUPH 1.4B
- IPO Year
- AIV 1994
- AUPH 1999
- Fundamental
- Price
- AIV $7.76
- AUPH $12.27
- Analyst Decision
- AIV Buy
- AUPH Strong Buy
- Analyst Count
- AIV 1
- AUPH 4
- Target Price
- AIV $10.00
- AUPH $12.25
- AVG Volume (30 Days)
- AIV 1.9M
- AUPH 2.8M
- Earning Date
- AIV 08-11-2025
- AUPH 07-31-2025
- Dividend Yield
- AIV 7.67%
- AUPH N/A
- EPS Growth
- AIV N/A
- AUPH N/A
- EPS
- AIV N/A
- AUPH 0.42
- Revenue
- AIV $212,439,000.00
- AUPH $260,111,000.00
- Revenue This Year
- AIV $6.96
- AUPH $12.15
- Revenue Next Year
- AIV N/A
- AUPH $18.34
- P/E Ratio
- AIV N/A
- AUPH $29.18
- Revenue Growth
- AIV 7.07
- AUPH 25.59
- 52 Week Low
- AIV $6.89
- AUPH $6.42
- 52 Week High
- AIV $9.49
- AUPH $12.53
- Technical
- Relative Strength Index (RSI)
- AIV 38.34
- AUPH 75.72
- Support Level
- AIV $7.59
- AUPH $11.74
- Resistance Level
- AIV $7.89
- AUPH $12.53
- Average True Range (ATR)
- AIV 0.26
- AUPH 0.44
- MACD
- AIV -0.04
- AUPH -0.00
- Stochastic Oscillator
- AIV 19.92
- AUPH 80.74
About AIV Apartment Investment and Management Company
Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment; Operating, and Other. Development and Redevelopment segment consists of properties that are under construction or have not achieved stabilization, as well as land held for development. Operating segment includes 20 residential apartment communities with 5,243 apartment homes that have achieved a stabilized level of operations. Other segment includes The Benson Hotel, company's only hotel. Majority of revenue is gained from Operating Segment.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.